We are live on ! Find out more
ARKG icon

ARK Genomic Revolution ETF

168 hedge funds and large institutions have $483M invested in ARK Genomic Revolution ETF in 2020 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 55 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more funds holding in top 10

Funds holding in top 10: 17 (+6)

420% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 15

293% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 14

179% more capital invested

Capital invested by funds: $173M → $483M (+$310M)

58% more funds holding

Funds holding: 106168 (+62)

2.93% more ownership

Funds ownership: 33.51%36.44% (+2.9%)

Holders
168
Holders Change
+62
Holders Change %
+58.49%
% of All Funds
3.44%
Holding in Top 10
7
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+600%
% of All Funds
0.14%
New
78
Increased
55
Reduced
14
Closed
15
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
HighTower Advisors
26
HighTower Advisors
Illinois
$4.9M +$325K +7,570 +9%
APA
27
American Portfolios Advisors
New York
$4.24M +$2.84M +66,308 +443%
Carson Wealth (CWM LLC)
28
Carson Wealth (CWM LLC)
Nebraska
$3.26M
BCM
29
Brookstone Capital Management
Illinois
$3.16M +$1.45M +33,698 +125%
SI
30
Stephens Inc
Arkansas
$3.15M +$2.59M +60,452 New
ACM
31
Avalon Capital Management
California
$3.02M +$2.48M +57,876 New
BFA
32
Brendel Financial Advisors
New Hampshire
$2.98M +$2.45M +57,104 New
Stifel Financial
33
Stifel Financial
Missouri
$2.79M +$1.29M +30,156 +129%
UAM
34
UAS Asset Management
New York
$2.61M +$2.15M +50,075 New
AWMS
35
Advocacy Wealth Management Services
Georgia
$2.35M +$1.93M +44,968 New
IAN
36
Integrated Advisors Network
Texas
$2.33M +$1.92M +44,707 New
JIP
37
Jaffetilchin Investment Partners
Florida
$2.28M +$1.07M +24,831 +131%
MIAN
38
Mariner Independent Advisor Network
Kansas
$2M +$1.08M +25,268 +207%
MML Investors Services
39
MML Investors Services
Massachusetts
$1.9M +$302K +7,030 +24%
JIR
40
James Investment Research
Ohio
$1.88M +$1.55M +36,106 New
PP
41
Prudential plc
United Kingdom
$1.49M +$1.22M +28,550 New
SA
42
Strategic Advisors
New York
$1.48M +$603K +14,057 +119%
LFGH
43
Lee Financial Group Hawaii
Hawaii
$1.42M +$1.17M +27,181 New
EWM
44
EPG Wealth Management
Georgia
$1.33M +$943K +21,980 +630%
DC
45
Davenport & Co
Virginia
$1.32M +$66.8K +1,558 +7%
MIC
46
Means Investment Company
Maine
$1.31M +$1M +23,369 New
HCA
47
Heck Capital Advisors
Wisconsin
$1.28M +$376K +8,761 +56%
SL
48
Stevard LLC
Illinois
$1.23M +$1.01M +23,517 New
TRCT
49
Tower Research Capital (TRC)
New York
$1.22M +$356K +8,307 +55%
VNA
50
Valley National Advisers
Pennsylvania
$1.05M -$44K -1,027 -5%

ARKG Hedge Fund Activity: Q2 2020 in Review

168 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q2 2020, worth a combined $483M — up 179% from $173M a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new ARKG positions and 15 closed out — a net gain of 63 holders — while 55 added to existing stakes and 14 trimmed.

The largest buyer was Mainstay Capital Management, adding an estimated $16.9M. The largest seller was Financial Engines Advisors, exiting entirely with an estimated $1.57M sold.

  • 168 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q2 2020, up from 106 in Q1 2020.
  • Funds reported $483M of ARK Genomic Revolution ETF stock for Q2 2020, up 179% quarter-over-quarter.
  • 78 funds opened new ARK Genomic Revolution ETF positions in Q2 2020 and 15 closed out, a net change of +63 holders.
  • The largest ARK Genomic Revolution ETF buyer in Q2 2020 was Mainstay Capital Management, an estimated $16.9M added.
  • The largest ARK Genomic Revolution ETF seller in Q2 2020 was Financial Engines Advisors, an estimated $1.57M sold.

Based on aggregated 13F filings for Q2 2020.